MedTrace Logo

Assessment Of Vascular Health After Niacin Therapy (AVANT)

NCT02003638 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2014-06-25

Study results available
· View outcomes & findings →

Summary

This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic statin therapy.

Conditions

Interventions

DRUG

Niacin

Niacin titrated to 6000 mg daily

DRUG

Placebo

Placebo provided in the same pill quantity as niacin arm

Sponsors & Collaborators

Principal Investigators

  • Emil deGoma, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003638 on ClinicalTrials.gov